Role of vildagliptin in managing type 2 diabetes mellitus in the elderly

References

• Fagot-Campagna A, Bourdel-Marchasson I, Simon D. Burden of diabetes in an aging population: prevalence, incidence, mortality, characteristics and quality of care. Diabetes Metab 2005;31 Spec No 2:5S35-5S52
   PubMed Web of Science ®Google Scholar
• Sloan FA, Bethel MA, Ruiz D Jr, et al. The growing burden of diabetes mellitus in the US elderly population. Arch Intern Med 2008;168:192-9
   PubMed Web of Science ®Google Scholar
• Diabetes UK. Diabetes in the UK 2004. London, UK: 2004. Available at: http://www.diabetes.org.uk/Documents/Reports/in_the_UK_2004.doc [Last accessed March 1, 2010]
   Google Scholar
• Doucet J. Use of antidiabetic drugs in elderly patients. Diabetes Metab 2005;31 Spec No 2:5S98-5S104
   Google Scholar
• Bourdel-Marchasson I, Doucet J, Bauduceau B, et al. Key priorities in managing glucose control in older people with diabetes. J Nutr Health Aging 2009;13:685-91
   PubMed Web of Science ®Google Scholar
• Zammitt NN, Frier BM. Hypoglycemia in type 2 diabetes: pathophysiology, frequency, and effects of different treatment modalities. Diabetes Care 2005;28:2948-61
   PubMed Web of Science ®Google Scholar
• Del Prato S, Heine RJ, Keilson L, et al. Treatment of patients over 64 years of age with type 2 diabetes: experience from nateglinide pooled database retrospective analysis. Diabetes Care 2003;26:2075-80
   PubMed Web of Science ®Google Scholar
• Cryer PE. The barrier of hypoglycemia in diabetes. Diabetes 2008;57:3169-76
   PubMed Web of Science ®Google Scholar
• Bremer JP, Jauch-Chara K, Hallschmid M, et al. Hypoglycemia unawareness in older compared with middle-aged patients with type 2 diabetes. Diabetes Care 2009;32:1513-17
   PubMed Web of Science ®Google Scholar
• Amiel SA, Dixon T, Mann R, et al. Hypoglycaemia in type 2 diabetes. Diabet Med 2008;25:245-54
   PubMed Web of Science ®Google Scholar
• Schernthaner G, Grimaldi A, Di Mario U, et al. GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients. Eur J Clin Invest 2004;34:535-42
   PubMed Web of Science ®Google Scholar
• Álvarez Guisasola F, Tofé Povedano S, Krishnarajah G, et al. Hypoglycaemic symptoms, treatment satisfaction, adherence and their associations with glycaemic goal in patients with type 2 diabetes mellitus: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) Study. Diabetes Obes Metab 2008;10(Suppl 1):25-32
   PubMed Web of Science ®Google Scholar
• Vexiau P, Mavros P, Krishnarajah G, et al. Hypoglycaemia in patients with type 2 diabetes treated with a combination of metformin and sulphonylurea therapy in France. Diabetes Obes Metab 2008;10(Suppl 1):16-24
   PubMed Web of Science ®Google Scholar
• United Kingdom Hypoglycaemia Study Group. Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia 2007;50:1140-7
   PubMed Web of Science ®Google Scholar
• Leiter LA, Yale J-F, Chiasson J-L, et al. Assessment of the impact of fear of hypoglycemic episodes on glycemic and hypoglycemic management. Can J Diabetes 2005;29:186-92
   Google Scholar
• Wild D, von Maltzahn R, Brohan E, et al. A critical review of the literature on fear of hypoglycemia in diabetes: implications for diabetes management and patient education. Patient Educ Couns 2007;68:10-15
   PubMed Web of Science ®Google Scholar
• Lundkvist J, Berne C, Bolinder B, et al. The economic and quality of life impact of hypoglycemia. Eur J Health Econ 2005;6:197-202
   PubMedGoogle Scholar
• Cryer PE, Davis SN, Shamoon H. Hypoglycemia in diabetes. Diabetes Care 2003;26:1902-12
   PubMed Web of Science ®Google Scholar
• Whitmer RA, Karter AJ, Yaffe K, et al. Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus. JAMA 2009;301:1565-72
   PubMed Web of Science ®Google Scholar
• Allicar MP, Megas F, Houzard S, et al. Frequency and costs of hospital stays for hypoglycemia in France in 1995 [in French]. Presse Med 2000;29:657-61
   PubMed Web of Science ®Google Scholar
• Nelson JM, Dufraux K, Cook PF. The relationship between glycemic control and falls in older adults. J Am Geriatr Soc 2007;55:2041-4
   PubMed Web of Science ®Google Scholar
• Desouza C, Salazar H, Cheong B, et al. Association of hypoglycemia and cardiac ischemia: a study based on continuous monitoring. Diabetes Care 2003;26:1485-9
   PubMed Web of Science ®Google Scholar
• Gill GV, Woodward A, Casson IF, et al. Cardiac arrhythmia and nocturnal hypoglycaemia in type 1 diabetes – the 'dead in bed' syndrome revisited. Diabetologia 2009;52:42-5
   PubMed Web of Science ®Google Scholar
• Wright RJ, Frier BM. Vascular disease and diabetes: is hypoglycaemia an aggravating factor?. Diabetes Metab Res Rev 2008;24:353-63
   PubMed Web of Science ®Google Scholar
• Duckworth W, Abraira C, Moritz T, et al, for the VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360:129-39
   PubMed Web of Science ®Google Scholar
• Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-59
   PubMed Web of Science ®Google Scholar
• Bonds DE, Miller ME, Bergenstal RM, et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ. 2010;340:b4909
   PubMed Web of Science ®Google Scholar
• Miller ME, Bonds DE, Gerstein HC, et al. The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study. BMJ 2010;340:b544
   Google Scholar
• Skyler JS, Bergenstal R, Bonow RO, et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Circulation 2009;119:351-7
   PubMed Web of Science ®Google Scholar
• Riddle MC. A1C and mortality in ACCORD. Diabetes 2009;58(Suppl 1). Abstract 468-P
   Google Scholar
• Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-72
   PubMed Web of Science ®Google Scholar
• Gradman TJ, Laws A, Thompson LW, et al. Verbal learning and/or memory improves with glycemic control in older subjects with non-insulin-dependent diabetes mellitus. J Am Geriatr Soc 1993;41:1305-12
   PubMed Web of Science ®Google Scholar
• Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-89
   PubMed Web of Science ®Google Scholar
• Doucet J, Le Floch JP, Bauduceau B, et al. What is the relationship between blood sugar and the morbidity and mortality at 5 years of type 2 diabetics aged 70 and over: GERODIAB project. Diabetes Metab 2009;35:A49
   PubMed Web of Science ®Google Scholar
• Vischer UM, Bauduceau B, Bourdel-Marchasson I, et al. A call to incorporate the prevention and treatment of geriatric disorders in the management of diabetes in the elderly. Diabetes Metab 2009;35:168-77
   PubMed Web of Science ®Google Scholar
• Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology Consensus Panel on Type 2 Diabetes Mellitus: an algorithm for glycemic control. Endocr Pract 2009;15:540-59
   PubMed Web of Science ®Google Scholar
• Bolen S, Feldman L, Vassy J, et al. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med 2007;147:386-99. Erratum in: Ann Intern Med 2007;147:887
   PubMed Web of Science ®Google Scholar
• Chelliah A, Burge MR. Hypoglycaemia in elderly patients with diabetes mellitus: causes and strategies for prevention. Drugs Aging 2004;21:511-30
   PubMed Web of Science ®Google Scholar
• Lecomte P. Diabetes in the elderly: considerations for clinical practice. Diabetes Metab 2005;31 Spec No 2:5S105-11
   Google Scholar
• Meneilly GS. Diabetes in the elderly. Med Clin North Am 2006;90:909-23
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65
   PubMed Web of Science ®Google Scholar
• Evans JM, Donnelly LA, Emslie-Smith AM, et al. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005;330:1304-5
   PubMed Web of Science ®Google Scholar
• Libby G, Donnelly LA, Donnan PT, et al. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 2009;32:1620-5
   PubMed Web of Science ®Google Scholar
• Li D, Yeung SC, Hassan MM, et al. Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology 2009;137:482-8
   PubMed Web of Science ®Google Scholar
• Gregorio F, Manfrini S, Testa I, et al. Metformin treatment in elderly type II diabetic patients. Arch Gerontol Geriatr 1996;22(Suppl 1):261-70
   PubMedGoogle Scholar
• Tahrani AA, Varughese GI, Scarpello JH, et al. Metformin, heart failure, and lactic acidosis: is metformin absolutely contraindicated?. BMJ 2007;335:508-12
   PubMed Web of Science ®Google Scholar
• Josse RG, Chiasson JL, Ryan EA, et al. Acarbose in the treatment of elderly patients with type 2 diabetes. Diabetes Res Clin Pract 2003;59:37-42
   PubMed Web of Science ®Google Scholar
• Halimi S, Le Berre MA, Grangé V. Efficacy and safety of acarbose add-on therapy in the treatment of overweight patients with type 2 diabetes inadequately controlled with metformin: a double-blind, placebo-controlled study. Diabetes Res Clin Pract 2000;50:49-56
   PubMed Web of Science ®Google Scholar
• Lipscombe LL, Gomes T, Levesque LE, et al. Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. JAMA 2007;298:2634-43
   PubMed Web of Science ®Google Scholar
• Schwartz AV, Sellmeyer DE, Vittinghoff E, et al. Thiazolidinedione use and bone loss in older diabetic adults. J Clin Endocrinol Metab 2006;91:3349-54
   PubMed Web of Science ®Google Scholar
• Fong DS, Contreras R. Glitazone use associated with diabetic macular edema. Am J Ophthalmol 2009;147:583-6
   PubMed Web of Science ®Google Scholar
• O'Kane MJ, Bunting B, Copeland M, et al. Efficacy of self monitoring of blood glucose in patients with newly diagnosed type 2 diabetes (ESMON study): randomised controlled trial. BMJ 2008;336:1174-7
   PubMed Web of Science ®Google Scholar
• Peel E, Douglas M, Lawton J. Self monitoring of blood glucose in type 2 diabetes: longitudinal qualitative study of patients' perspectives. BMJ 2007;335:493
   PubMed Web of Science ®Google Scholar
• Mathieu C, Bollaerts K. Antihyperglycaemic therapy in elderly patients with type 2 diabetes: potential role of incretin mimetics and DPP-4 inhibitors. Int J Clin Pract Suppl 2007;154:29-37
   PubMedGoogle Scholar
• Abbatecola AM, Maggi S, Paolisso G. New approaches to treating type 2 diabetes mellitus in the elderly: role of incretin therapies. Drugs Aging 2008;25:913-25
   PubMed Web of Science ®Google Scholar
• Fonseca V, Schweizer A, Albrecht D, et al. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia 2007;50:1148-55
   PubMed Web of Science ®Google Scholar
• Garber AJ, Schweizer A, Baron MA, et al. Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study. Diabetes Obes Metab 2007;9:166-74
   PubMed Web of Science ®Google Scholar
• Pi-Sunyer FX, Schweizer A, Mills D, et al. Efficacy and tolerability of vildagliptin monotherapy in drug-naive patients with type 2 diabetes. Diabetes Res Clin Pract 2007;76:132-8
   PubMed Web of Science ®Google Scholar
• Pratley RE, Rosenstock J, Pi-Sunyer FX, et al. Management of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapy. Diabetes Care 2007;30:3017-22
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Baron MA, Dejager S, et al. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Care 2007;30:217-23
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Baron MA, Camisasca R-P, et al. Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes. Diabetes Obes Metab 2007;9:175-85
   PubMed Web of Science ®Google Scholar
• Schweizer A, Couturier A, Foley JE, et al. Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug-naïve patients with type 2 diabetes. Diabet Med 2007;24:955-61
   PubMed Web of Science ®Google Scholar
• Bolli G, Dotta F, Rochotte E, et al. Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study. Diabetes Obes Metab 2008;10:82-90
   PubMed Web of Science ®Google Scholar
• Garber AJ, Foley JE, Banerji MA, et al. Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea. Diabetes Obes Metab 2008;10:1047-56
   PubMed Web of Science ®Google Scholar
• Garber AJ, Sharma MD. Update: vildagliptin for the treatment of type 2 diabetes. Expert Opin Investig Drugs 2008;17:105-13
   PubMed Web of Science ®Google Scholar
• Scherbaum WA, Schweizer A, Mari A, et al. Efficacy and tolerability of vildagliptin in drug-naive patients with type 2 diabetes and mild hyperglycaemia. Diabetes Obes Metab 2008;10:675-82
   Google Scholar
• Ferrannini E, Fonseca V, Zinman B, et al. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes Obes Metab 2009;11:157-66
   PubMed Web of Science ®Google Scholar
• Goodman M, Thurston H, Penman J. Efficacy and tolerability of vildagliptin in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Horm Metab Res 2009;41:368-73
   PubMed Web of Science ®Google Scholar
• Schweizer A, Dejager S, Bosi E. Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Obes Metab 2009;11:804-12
   PubMed Web of Science ®Google Scholar
• Ligueros-Saylan M, Foley JE, Schweizer A, et al. An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of phase II and III clinical trials. Diabetes Obes Metab 2010;12:495–509
   Google Scholar
• Ayalasomayajula SP, Dole K, He YL, et al. Evaluation of the potential for steady-state pharmacokinetic interaction between vildagliptin and simvastatin in healthy subjects. Curr Med Res Opin 2007;23:2913-20
   PubMed Web of Science ®Google Scholar
• He YL, Sabo R, Sunkara G, et al. Evaluation of pharmacokinetic interactions between vildagliptin and digoxin in healthy volunteers. J Clin Pharmacol 2007;47:998-1004
   PubMed Web of Science ®Google Scholar
• He YL, Sabo R, Riviere GJ, et al. Effect of the novel oral dipeptidyl peptidase IV inhibitor vildagliptin on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Curr Med Res Opin 2007;23:1131-8
   PubMed Web of Science ®Google Scholar
• He YL, Ligueros-Saylan M, Sunkara G, et al. Vildagliptin, a novel dipeptidyl peptidase IV inhibitor, has no pharmacokinetic interactions with the antihypertensive agents amlodipine, valsartan, and ramipril in healthy subjects. J Clin Pharmacol 2008;48:85-95
   PubMed Web of Science ®Google Scholar
• Serra D, He YL, Bullock J, et al. Evaluation of pharmacokinetic and pharmacodynamic interaction between the dipeptidyl peptidase IV inhibitor vildagliptin, glyburide and pioglitazone in patients with type 2 diabetes. Int J Clin Pharmacol Ther 2008;46:349-64
   PubMed Web of Science ®Google Scholar
• Scherbaum WA, Schweizer A, Mari A, et al. Evidence that vildagliptin attenuates deterioration of glycaemic control during 2-year treatment of patients with type 2 diabetes and mild hyperglycaemia. Diabetes Obes Metab 2008;10:1114-24
   PubMed Web of Science ®Google Scholar
• Devendra D, Gohel B, Bravis V, et al. Vildagliptin therapy and hypoglycaemia in Muslim type 2 diabetes patients during Ramadan. Int J Clin Pract 2009;63:1446-50
   PubMed Web of Science ®Google Scholar
• Dunning BE, Foley JE, Ahrén B. Alpha cell function in health and disease: influence of glucagon-like peptide-1. Diabetologia 2005;48:1700-13
   PubMed Web of Science ®Google Scholar
• Degn KB, Brock B, Juhl CB, et al. Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia. Diabetes 2004;53:2397-403
   PubMed Web of Science ®Google Scholar
• El Ouaghlidi A, Rehring E, Holst JJ, et al. The dipeptidyl peptidase 4 inhibitor vildagliptin does not accentuate glibenclamide-induced hypoglycemia but reduces glucose-induced glucagon-like peptide 1 and gastric inhibitory polypeptide secretion. J Clin Endocrinol Metab 2007;92:4165-71
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Foley JE, Rendell M, et al. Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance. Diabetes Care 2008;31:30-5
   PubMed Web of Science ®Google Scholar
• Ahrén B, Landin-Olsson M, Jansson P-A, et al. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab 2004;89:2078-84
   PubMed Web of Science ®Google Scholar
• Ahrén B, Foley JE, Ferrannini E, et al. Changes in prandial glucagon levels after 2-year treatment with vildagliptin or glimepiride in patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy. Diabetes Care 2010 Jan 12. [Epub ahead of print]
   Google Scholar
• Ahrén B, Schweizer A, Dejager S, et al. Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes. J Clin Endocrinol Metab 2009;94:1236-43
   PubMed Web of Science ®Google Scholar
• Fonseca V, Baron M, Shao Q, et al. Sustained efficacy and reduced hypoglycemia during one year of treatment with vildagliptin added to insulin in patients with type 2 diabetes mellitus. Horm Metab Res 2008;40:427-30
   PubMed Web of Science ®Google Scholar
• Basu R, Breda E, Oberg AL, et al. Mechanisms of the age-associated deterioration in glucose tolerance: contribution of alterations in insulin secretion, action and clearance. Diabetes 2003;52:1738-48
   PubMed Web of Science ®Google Scholar
• Chang AM, Halter JB. Aging and insulin secretion. Am J Physiol Endocrinol Metab 2003;284:E7-12
   PubMed Web of Science ®Google Scholar
• Bosi E, Camisasca RP, Collober C, et al. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care 2007;30:890-5
   PubMed Web of Science ®Google Scholar
• Pratley RE, Schweizer A, Rosenstock J, et al. Robust improvements in fasting and prandial measures of β-cell function with vildagliptin in drug-naïve patients: analysis of pooled vildagliptin monotherapy database. Diabetes Obes Metab 2008;10:931-8
   PubMed Web of Science ®Google Scholar